

Interleukin 7 (IL-7) selectively promotes mouse and human IL-17–producing $\gamma\delta$ cells

Marie-Laure Michel^{a,b}, Dick J. Pang^c, Syeda F. Y. Haque^b, Alexandre J. Potocnik^d, Daniel J. Pennington^c, and Adrian C. Hayday^{a,b,1}

^aLondon Research Institute, Cancer Research UK, London WC2A 3LY, United Kingdom; ^bThe Peter Gorer Department of Immunobiology, King's College London, Guy's Hospital, London SE19RT, United Kingdom; ^cThe Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London E12AT, United Kingdom; and ^dDivision of Molecular Immunology, Medical Research Council National Institute for Medical Research, London NW71AA, United Kingdom

Edited by Robert L. Coffman, Dynavax Technologies, Berkeley, CA, and approved September 18, 2012 (received for review March 14, 2012)

IL-17–producing CD27[−] $\gamma\delta$ cells ($\gamma\delta^{27−}$ cells) are widely viewed as innate immune cells that make critical contributions to host protection and autoimmunity. However, factors that promote them over IFN- γ –producing $\gamma\delta^{27+}$ cells are poorly elucidated. Moreover, although human IL-17–producing $\gamma\delta$ cells are commonly implicated in inflammation, such cells themselves have proved difficult to isolate and characterize. Here, murine $\gamma\delta^{27−}$ T cells and thymocytes are shown to be rapidly and substantially expanded by IL-7 *in vitro* and *in vivo*. This selectivity owes in substantial part to the capacity of IL-7 to activate STAT3 in such cells. Additionally, IL-7 promotes strong responses of IL-17–producing $\gamma\delta$ cells to TCR agonists, thus reemphasizing the cells' adaptive and innate potentials. Moreover, human IL-17–producing $\gamma\delta$ cells are also substantially expanded by IL-7 plus TCR agonists. Hence, IL-7 has a conserved potential to preferentially regulate IL-17–producing $\gamma\delta$ cells, with both biological and clinical implications.

lymphocytes | cytokines | proliferation

Studies of IL-17 intensified with the identification of a specific subset of CD4⁺ Th17 cells that upon activation primarily produces IL-17 as opposed to IFN- γ (Th1 cells), IL-4 (Th2 cells), or IL-10/TGF β (Treg cells) (1–3). Th17 differentiation is regulated by transcription factors ROR γ t and STAT3, the latter in part explaining the promotion of Th17 differentiation by IL-6 and IL-23 (3). Paradoxically, more detailed studies of Th17 immunity have identified $\gamma\delta$ T cells and/or innate-like lymphoid cells as critical initial producers of IL-17 (4, 5). At steady-state, $\gamma\delta$ cells are only a minor subset of T lymphocytes, but upon infection by *Listeria*, *Mycobacteria*, or *Plasmodium*, or upon LPS administration, they expand and make critical contributions to host protection (5–9). They likewise underpin immunopathology in widely used models of inflammatory disease (10, 11). In humans, IL-17 protects against mucocutaneous candidiasis and is again implicated in autoimmune inflammation, including psoriasis, multiple sclerosis, and rheumatoid arthritis (12, 13). Hence, there is considerable interest in identifying factors that regulate IL-17–producing $\gamma\delta$ cells in mice and humans.

Adding to this interest is the emergence of murine $\gamma\delta$ cells as prime examples of thymic preprogramming, whereby functional distinctions between CD27⁺IFN- γ producers ($\gamma\delta^{27+}$ cells) and CD27[−]IL-17–producing ($\gamma\delta^{27−}$) cells are established by developmental cues that are largely unelucidated (8, 14). For example, $\gamma\delta^{27−}$ cells seem largely to arise from fetal thymocytes, requiring neither engagement of cognate ligand, nor ROR γ t or STAT3 that are both required for TCR $\alpha\beta$ ⁺ Th17 cell development (15). However, despite the dispensability of ROR γ t and STAT3 in development, most peripheral IL-17–producing $\gamma\delta$ cells express ROR γ t and respond rapidly to IL-23 that signals via STAT3 (10). Such rapid responsiveness in the absence of TCR stimulation has led many to classify $\gamma\delta^{27−}$ cells as innate immune cells: Indeed, they generally respond poorly to concentrations of TCR agonists that would promote robust activation of $\gamma\delta^{27+}$ cells (9). Nonetheless, assigning IL-17–producing $\gamma\delta$ cells to innate immunity seems premature until more is known about what regulates the cells and how that might influence their response to TCR stimulation.

Although IL-17–producing $\gamma\delta$ cells are likewise commonly evoked in human immune responses and immunopathologies, very little is known about these cells, because they have proved particularly hard to isolate and characterize (16). Thus, it seemed logical that by elucidating stimuli for murine $\gamma\delta^{27−}$ cells, one might identify the means to expand their human counterparts. This study identifies IL-7 as a profound and selective activator of IL-17–producing $\gamma\delta$ cells in mouse and in human neonates.

Results

IL-7 Enriches for Lymph Node $\gamma\delta^{27−}$ Cells. Lymph node (LN) $\gamma\delta^{27+}$ cells appear like naive conventional T cells, being primarily CD62L⁺ CD25[−] CD44^{lo} ICOS[−], whereas between 50% and 75% of $\gamma\delta^{27−}$ cells resemble activated T cells (CD62L[−] CD25^{+/−} CD44^{hi} ICOS⁺), although they are largely CD69[−] (Fig. 1A and Fig. S1A). As was reported (17), $\gamma\delta^{27−}$ cells also express higher levels of IL-7R than do $\gamma\delta^{27+}$ cells (Fig. 1A). To determine whether this phenotype had functional implications, LN cells were cultured with IL-7 for 4 d. Over eight independent experiments, $\gamma\delta^{27−}$ cells were strikingly enriched ~five- to sevenfold relative to $\gamma\delta^{27+}$ cells and ~6- to 10-fold relative to total LN cells, whereas $\alpha\beta$ T-cell numbers declined (Fig. 1B and Fig. S1B and C). Essentially all $\gamma\delta^{27−}$ cells were TCR^{hi} CD44^{hi}, and now ~70% expressed CD69 (Fig. 1B and C). IL-7 also increased the proportion of $\gamma\delta^{27+}$ cells expressing CD44 and CD69 (Fig. 1C), although their numbers declined ~70% over 4 d, whereas absolute numbers of $\gamma\delta^{27−}$ cells increased three- to fourfold (Fig. 1D). Strikingly, this enrichment was for cells with IL-17–producing capacity, whose representation increased from ~30% to ~70% of the $\gamma\delta^{27−}$ subset (Fig. 1E). Consistent with this increase, IL-7 enriched for cells expressing ROR γ t protein but not for those expressing T-bet, a primary regulator of IFN- γ (Fig. S1D).

To probe the generality of these observations, we investigated cells from the peritoneal cavity, known to harbor IL-17–producing $\gamma\delta$ T cells (18, 19). Ex vivo almost all $\gamma\delta$ cells were CD44^{hi} (Fig. S1E), and they were enriched after 4 d in IL-7, compared with total cells (Fig. S1E and F). However, whereas IL-7 maintained $\gamma\delta^{27+}$ cell numbers *in vitro* relative to culture in medium alone, absolute numbers of $\gamma\delta^{27−}$ cells were again increased: ~ninefold relative to medium alone, and ~fourfold relative to numbers harvested ex vivo (Fig. S1G). Among these cells, the proportion of IL-17 producers was again increased (Fig. S1H). Thus, IL-7 preferentially enriches for IL-17–competent $\gamma\delta$ T cells from two distinct anatomical sources.

Author contributions: M.-L.M., D. J. Pennington, and A.C.H. designed research; M.-L.M., D. J. Pang, and S.F.Y.H. performed research; A.J.P. contributed new reagents/analytic tools; M.-L.M., D. J. Pang, S.F.Y.H., A.J.P., D. J. Pennington, and A.C.H. analyzed data; and M.-L.M. and A.C.H. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.

¹To whom correspondence should be addressed. E-mail: adrian.hayday@kcl.ac.uk.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1204327109/-DCSupplemental.




Fig. 1. IL-7 enriches for IL-17-competent $\gamma\delta$ T cells. (A) $\gamma\delta$ T cells from lymph nodes (LN) of adult mice, stained for CD44, CD69, IL-7R, and CD27. (B) Representative plots (from $n = 8$ experiments) of total LN cells, ex vivo (Left) and after 4-d culture in vitro with IL-7 (Right). (C) Surface staining of $\gamma\delta$ T cells after 4-d culture in vitro with IL-7. (D) Absolute numbers of CD44^{lo} and CD44^{hi} $\gamma\delta^{27+}$ cells and CD44^{lo} and CD44^{hi} $\gamma\delta^{27-}$ cells from LN cells cultured as in B. Error bars are SEM from $n = 8$ experiments: * $P < 0.05$, *** $P < 0.0005$. (E) Intracellular staining for IL-17 in $\gamma\delta$ T cells from LN cells cultured as in B and then activated with PMA + ionomycin.

To examine whether the same effects would be achieved in vivo, mice were administered recombinant IL-7 three times over 5 d and then examined on day 7. There was a conspicuous

enrichment of CD44^{hi} $\gamma\delta^{27-}$ cells, with absolute numbers of LN $\gamma\delta$ cells competent to make IL-17 upon activation increasing >fivefold, compared with two- to threefold increases in IFN- γ -competent cells (Fig. 2 A–C). Note that before and after IL-7 treatment, few $\gamma\delta$ cells coproduced IL-17 and IFN- γ , consistent with developmental preprogramming (8).

To test whether IL-7 is required for the expansion of IL-17-producing $\gamma\delta$ cells in vivo, we examined mice treated epicutaneously with imiquimod (IMQ) in which the development of acute psoriaform lesions is largely attributable to expansion of IL-17-producing $\gamma\delta$ cells in the skin and skin-draining LNs (11, 20). Indeed, such lesions are comparable in WT and $\alpha\beta$ T-cell-deficient mice but dramatically reduced in TCR $\delta^{-/-}$ mice (11, 20). Administration of anti-IL-7R antibody almost completely blocked the enrichment (~ 10 -fold) in IL-17⁺ $\gamma\delta$ cells in the skin-draining LNs of mice administered IMQ versus vaseline but did not significantly limit the two- to threefold expansion of IFN- γ ⁺ $\gamma\delta$ cells (Fig. 2 D and E). Skin erythema scores, which compose a highly reproducible marker of IMQ-induced pathology, were significantly reduced in anti-IL-7R-treated animals (Fig. 2F), as was epidermal thickening that is associated with dermal IL-17-producing $\gamma\delta$ cell expansion (11, 20). That some reddening nonetheless occurred most likely reflects widely acknowledged nonimmunological effects of IMQ (20).

Mechanism of Enrichment. Directly ex vivo, few $\gamma\delta^{27+}$ and $\gamma\delta^{27-}$ cells were dividing as judged by Ki67 staining, but after 4 d in IL-7, >90% of $\gamma\delta^{27-}$ cells were dividing compared with only $\sim 30\%$ for $\gamma\delta^{27+}$ cells (black versus gray lines; Fig. 3A). Furthermore, when cells were labeled ex vivo with a membrane-intercalating dye, carboxy-fluorescein diacetate succinimidyl ester (CFSE), $\gamma\delta^{27-}$ cells showed much greater dye dilution (by cell division) than did $\gamma\delta^{27+}$ cells (Fig. 3B), and it was those dividing cells that accounted for almost all IL-17 production upon stimulation (Fig. 3C). Hence, IL-7 drives the preferential expansion of $\gamma\delta^{27-}$ cells with, by contrast, little evidence of selective survival: indeed, *Bcl-2* mRNA whose up-regulation has been associated with antiapoptotic effects of IL-7 in T cells (21) was more strongly expressed by $\gamma\delta^{27+}$ cells (Fig. S24).

IL-7 signals are primarily transduced by STAT5 and PI3-kinase (22–24). However, IL-7-dependent STAT5 phosphorylation was comparable among $\gamma\delta^{27+}$ cells and $\gamma\delta^{27-}$ cells (Fig. 3D),




Fig. 2. IL-7 enriches in vivo for IL-17-competent $\gamma\delta$ T cells. (A) Representative plots ($n = 3$) of $\gamma\delta$ T cells from total adult LNs from mice treated with PBS (Left) and IL-7 (Right). For all plots, numbers indicate percent of cells in relevant quadrant. (B) Intracellular staining for IL-17 and IFN- γ in gated $\gamma\delta$ T cells, from mice treated as in A, and then activated in vitro with PMA + ionomycin. (C) Absolute numbers of IL-17⁺ and IFN- γ ⁺ $\gamma\delta$ T cells from mice treated as in B. Error bars are SEM from $n = 3$ mice; * $P < 0.05$. (D) Mice were treated with Vaseline (Ctrl; Upper) or imiquimod (IMQ; Lower) and anti-IL-7R Ab (Right) or isotype control (Left). Intracellular staining for IL-17 and IFN- γ in $\gamma\delta$ T cells from LN cells, activated with PMA + ionomycin. (E) Absolute numbers of IL-17⁺ and IFN- γ ⁺ $\gamma\delta$ cells obtained as described in D (error bars are SEM from two experiments, $n = 8$ mice in total, * $P < 0.05$). (F) Score for skin erythema from mice treated with IMQ as in D (from 4 experiments, $n = 16$ mice in total, $P < 0.005$).




Fig. 3. IL-7 promotes expansion of IL-17-competent $\gamma\delta$ T cells via selective STAT3 activation. (A) Staining for Ki67 (cells in cycle) in gated $\gamma\delta^{27-}$ (Left) and $\gamma\delta^{27+}$ (Right) LN cells ex vivo (gray line) and after 4-d culture with IL-7 (black line). Shaded histograms show Ki67 isotype staining. (B) Offset histograms of $\gamma\delta^{27-}$ (blue) and $\gamma\delta^{27+}$ (red) LN cells labeled with CFSE and then cultured for 4 d with IL-7. Shaded gray area represents $\gamma\delta$ T cells stained ex vivo. (C) CFSE-labeled LN cells were cultured for 4 d with IL-7, activated with PMA + ionomycin and stained for intracellular IL-17 and gated on $\gamma\delta$ cells. (D) Flow cytometric detection of intracellular pSTAT5 and pSTAT3 in gated $\gamma\delta^{27-}$ and $\gamma\delta^{27+}$ cells as labeled. Open and shaded areas indicate IL-7 treatment and controls, respectively. (E) Intracellular localization by ImageStream Flow Cytometry of pSTAT3 among two representative $CD44^{hi}$ $\gamma\delta^{27-}$ (Upper) and $CD44^{lo}$ $\gamma\delta^{27+}$ (Lower) LN cells after 30-min culture with IL-7 (BF, Bright field). (F) LN cells preincubated with a specific STAT3 inhibitor and subsequently cultured with IL-7 for 72 h. Representative plots (from $n = 3$ experiments). (G) Staining for Ki67 and intracellular IL-17 in gated $\gamma\delta$ T cells cultured as in F; open and shaded areas indicate STAT3 inhibitor preincubation and controls, respectively. For all plots, numbers indicate percent of cells in relevant gate or quadrant.

failing to account for the differential effects of IL-7 on $\gamma\delta^{27-}$ cells. In fact, STAT5 activation antagonizes Th17 differentiation (25) in which regard the promotion of IL-17-producing cells by IL-7 seemed paradoxical. However, IL-7 may also activate STAT3 (22) which mediates the effects of cytokines known to promote IL-17-producing $\gamma\delta$ T cells (10): indeed, after IL-7 stimulation $\gamma\delta^{27-}$ cells showed >threefold higher phospho-STAT3 expression than $\gamma\delta^{27+}$ cells (Fig. 3D). This phosphorylation was largely limited to $CD44^{hi}$ cells, in which most pSTAT3 was nuclear, as illustrated by colocalization with propidium iodide (Fig. 3E and Fig. S2C). In *I17aCreR26ReYFP* “fate mapping” mice, cells transcribing the *I17a* locus induce *cre* that excises a stop codon, thereby irreversibly activating an enhanced yellow fluorescent protein (eYFP) gene in the *rosa26* locus (26). LN eYFP⁺ $\gamma\delta$ cells are $CD44^{hi}$ and $ROR\gamma t^{+}$ (Fig. S2D), and after 30-min stimulation with IL-7, pSTAT3 was selectively expressed by eYFP⁺ $\gamma\delta$ cells (Fig. S2E).

When LN cells were incubated for 3 d with IL-7 in the presence or absence of an inhibitor that blocks STAT3 phosphorylation but leaves STAT5 phosphorylation intact (Fig. S2F), $\gamma\delta^{27+}$ cells were little affected, whereas the preferential enrichment of $\gamma\delta^{27-}$ cells was

reduced by >50%, with a corresponding reduction in Ki67⁺ cells, and very severe attenuation of cells with IL-17-producing potential (Fig. 3 F and G and Fig. S2G). This effect was not attributable to any toxicity of the inhibitor; for example, $\gamma\delta^{27-}$ annexin-V profiles were equivalent with or without it (Fig. S2H). Correlating with the selective IL-7-mediated activation of STAT3 in $\gamma\delta^{27-}$ cells were very low levels of the STAT3 suppressor, SOCS3, relative to $CD44^{lo}$ $\gamma\delta^{27+}$ cells (Fig. S2I). Interestingly, the minor $CD44^{hi}$ $\gamma\delta^{27+}$ subset also expressed low levels of SOCS3, perhaps accounting for the maintenance of these cells in IL-7 compared with the loss of bulk $\gamma\delta^{27+}$ cells (Fig. 1D).

IL-7 Enriches for $\gamma\delta^{27-}$ Thymocytes. IL-17-producing $\gamma\delta^{27-}$ cells reportedly arise during fetal thymic development (4, 18), although




Fig. 4. IL-7 enriches for IL-17-competent $\gamma\delta$ thymocytes. (A and B) Histograms for IL-7R staining of: adult $\gamma\delta^{27-}$ (black line) and $\gamma\delta^{27+}$ (gray line) thymocytes ex vivo (A); $\gamma\delta^{27-}$ cells expressing IL-17 (black line) or not expressing IL-17 (gray line) after PMA + ionomycin activation (B). Gray shaded area is isotype control staining. (C) *I17* mRNA levels in sorted $\gamma\delta^{27+}$, and IL-7R^{lo} and IL-7R^{hi} $\gamma\delta^{27-}$ thymocytes determined by real-time RT-PCR. (D) Total thymocytes from adult mice ex vivo or activated for 4 d in vitro with IL-7 (Left); CD44 and CD27 expression among gated $\gamma\delta$ T cells (Center Left); Intracellular staining for IFN- γ and IL-17 in all $\gamma\delta$ T cells (Center Right) and $\gamma\delta^{27-}$ cells (Right) after PMA + ionomycin activation. For all plots, numbers indicate percent of cells in relevant gate or quadrant. (E) Adult thymocytes preincubated with a specific STAT3 inhibitor (Lower) or vehicle control (Upper) and subsequently cultured with IL-7 for 72 h. Representative plots (from $n = 3$ experiments) of gated $\gamma\delta$ T cells. (F) Percentage and absolute numbers of eYFP⁺ $\gamma\delta^{27-}$ and eYFP⁻ $\gamma\delta^{27-}$ thymocytes from adult *I17a-CreR26ReYFP* mice ex vivo (black bars) or after culture with IL-7 for 4 d (open bars). (G) $\gamma\delta$ cells stained for IL-17 and IFN- γ after 7-d FTOC from embryonic day 16.5 fetal thymus in the presence (Right) or absence (Left) of IL-7 (from $n = 3$ experiments with ≥ 3 thymic lobes per condition).

they can easily be found in the thymus of adult mice, where they express conspicuously high levels of IL-7R (Fig. 4*A* and *B*). High levels of *Il17* mRNA were consistently detected only among IL-7R^{hi}γδ²⁷⁻ cells (Fig. 4*C*). IL-7 is absolutely required for γδ cell development, and culture with IL-7 fueled the survival and expansion of all adult γδ thymocytes, as shown by a time course (Fig. S3*A*). Nonetheless, there was again a strong enrichment for CD44^{hi}IL-17-competent, TCR^{hi} CD27⁻ γδ cells, with such cells transitioning from the minority to the majority by comparison to IFN-γ-competent cells (Fig. 4*D* and Fig. S3*A*).

As for LN cells, CFSE labeling and Ki67 staining of thymocytes ex vivo showed that IL-7 primarily promoted proliferation of CD44^{hi}CD27⁻ thymocytes with IL-17 potential (Fig. S3*B* and *C*): Indeed, after 4 d, >90% of CD44^{hi}CD27⁻ thymocytes were cycling with >98% of IL-17-competent cells found among these. Again there was little evidence for IL-7-mediated selective survival of γδ²⁷⁻ cells with *Bcl-2* mRNA levels lower in γδ²⁷⁻ cells than in γδ²⁷⁺ cells (Fig. S3*D*). The preferential expansion of CD44⁺γδ²⁷⁻ thymocytes was reduced ≥80% by the STAT3 inhibitor (Fig. 4*E* and Fig. S3*E*). Conspicuously, thymic γδ²⁷⁻ cells were not selectively enriched by other STAT5- (IL-2, IL-15, and IL-21) and STAT3- (IL-6) activating cytokines, either alone or added to suboptimal concentrations of IL-7. IL-2 activated all γδ thymocytes, but still enriched (almost twofold) for γδ²⁷⁺ cells, whereas IL-15 primarily activated γδ²⁷⁺ cells (Fig. S4). Thus, as for LN cells, IL-7 promotes preferential STAT3-dependent expansion of IL-17-competent γδ²⁷⁻ thymocytes.

Further evidence that IL-7 preferentially expands IL-17-competent thymocytes within the γδ²⁷⁻ subset was derived from the Il17aCreR26ReYFP mice. Ex vivo ~1% of γδ thymocytes are eYFP⁺CD27⁻, whereas ~8% are eYFP⁻CD27⁻ (Fig. 4*F*), roughly consistent with ~11% of γδ²⁷⁻ thymocytes producing IL-17 upon short-term activation (Fig. 4*D*, Upper). Conversely, 4 d in IL-7 increased eYFP⁺CD27⁻ cell numbers >30-fold, making them the larger subset compared with eYFP⁻CD27⁻ cells that had increased much less (Fig. 4*F*).

To demonstrate that developing γδ²⁷⁻ cells are a preferential target of IL-7, fetal thymocytes were examined because the fetal thymus will not be a target for peripheral T-cell recirculation. Supplemental IL-7 added to 7-d fetal thymic organ culture (FTOC) expanded absolute numbers of total γδ thymocytes by ~fivefold, but again the impact was preferential for IL-17-competent γδ thymocytes whose representation was increased twofold over IFN-γ-producing γδ thymocytes (Fig. 4*G*). To verify that IL-7 preferentially activated γδ²⁷⁻ thymocytes rather than promoting the conversion of γδ²⁷⁺ thymocytes to γδ²⁷⁻ cells, IL-7 was applied to purified CD44^{hi}γδ²⁷⁻, CD44^{hi}γδ²⁷⁺, or CD44^{lo}γδ²⁷⁺ thymocytes. After a 4-d culture, CD44^{hi}γδ²⁷⁻ cells appeared by microscopy to be highly activated, by contrast to the γδ²⁷⁺ subsets. To normalize the number of cells in the cultures, purified subsets were admixed with thymocytes from age-matched TCRδ^{-/-} mice. Strikingly, neither γδ²⁷⁺ subset generated IL-17-competent cells over 4 d, whereas >70% of cells arising from only 5,000 CD44^{hi}γδ²⁷⁻ were IL-17 competent (Fig. S5). Thus, IL-7 primarily expands cells with IL-17 competence rather than differentiating cells toward IL-17 de novo.

IL-7 Promotes Adaptive Potential to Produce IL-17. IL-17-producing γδ cells are widely viewed as innate because they are rapidly activated by IL-1 and IL-23 alone and are relatively unresponsive to TCR agonists that strongly activate IFN-γ-producing γδ²⁷⁺ cells (Fig. S6*A*) (9). However, in the presence of IL-7, TCR agonists promoted a >20-fold enrichment of γδ²⁷⁻ cells relative to LN cells, whereas γδ²⁷⁺ cells were enriched by only three- to fourfold: By 4 d, ~100% of γδ²⁷⁻ cells were CD69⁺CD44^{hi}CD25⁺ ICOS⁺ (Fig. 5*A* and *B* and Fig. S6*B*). Compared with IL-7 alone, suboptimal concentrations of TCR agonists added to IL-7 increased γδ²⁷⁻ IL-17-competent cell numbers by an additional 40–50% (Fig. 5*C* and *D*), whereas there was negligible synergy for γδ²⁷⁺ cells, which instead responded very strongly to the combination of IL-15 + TCR agonists (Fig. S6*C* and *D*).

As a preface to killing target cells in response to TCR-mediated activation, T cells exocytose the contents of cytolytic




Fig. 5. TCR agonists and IL-7 cooperatively promote IL-17-producing γδ cells. (A) Total LN cells stained for markers as indicated ex vivo (Left) and after 4-d culture with IL-7 + 1 μg/mL TCR-agonist antibody [GL3] (Right) or isotype control (Center). (B) LN γδ T cells stained for markers as indicated after 4-d culture with IL-7 and either TCR-agonist antibody (Lower) or isotype control (Upper). For all plots, numbers indicate percent of cells in relevant quadrants. (C) Absolute number of total γδ²⁷⁻ (Upper) or IL-17-expressing γδ²⁷⁻ (Lower) LN cells after culture in IL-7 with 1 μg/mL GL3 or IgG control, as in A. Error bars are SEM from *n* = 3 experiments; **P* < 0.05. (E) Staining for CD107 in gated γδ²⁷⁻ (Left) and γδ²⁷⁺ (Right) cells, activated for 6 h with 10 μg/mL TCR agonists (line) or isotype control (shaded area), from ex vivo LN (Left) and after 4-d culture with IL-7 (Right).

granules in a process that involves movement to the cell surface of the protein CD107a (27). Hence, CD107a expression levels provided an additional assay for the impact of IL-7 on the response of γδ T cells to TCR stimulation. Strikingly, TCR agonists provoked surface up-regulation of CD107a by γδ²⁷⁻ cells only after the cells' culture in IL-7, whereas γδ²⁷⁺ cells up-regulated CD107a expression directly ex vivo, with no requirement for IL-7 (Fig. 5*E*). In sum, IL-7 selectively facilitates strong responses of IL-17-producing γδ cells to TCR stimulation whether measured by expansion, activation markers, or effector function.

IL-7 Reveals IL-17-Competent Human γδ Cells. By contrast to mice, a substantive subset of IL-17-producing human γδ T cells has been hard to identify in healthy donors (16, 28). As reported (29), there was precocious production of IFN-γ by fresh human cord blood (CB) γδ cells and by adult TCRγδ⁺ peripheral blood mononuclear cells (PBMC) stimulated by PMA + ionomycin, but there was no obvious IL-17-producing subset (Fig. 6*A*). When PBMC were cultured for 1 wk with anti-TCRγδ + IL-7 and then activated for 6 h, IFN-γ monoproducers described ~80% of cells; a small percentage coexpressed IL-17 and IFN-γ, but there was still no IL-17 monoproducer (Fig. 6*B*). However, when CB cells were likewise cultured, substantial fractions of Vδ2⁺ and Vδ1⁺ cells produced IL-17 with most being IL-17-monoproducers (Fig. 6*B* and Fig. S7*A*). Unsurprisingly, the percentages of γδ cells that were IL-17-competent varied with the source of CB from ~15% to >40%, with higher representation always being among Vδ2⁺ cells: Indeed, IL-17-competent Vδ2⁺ cells sometimes outnumbered




Fig. 6. Evocation of IL-17-producing $\gamma\delta$ T cells from human cord blood. Representative plots from $n \geq 4$ donors. (A and B) Intracellular staining for IFN- γ and IL-17 in $V\delta 1^+$ (Upper) and $V\delta 2^+$ (Lower) cells from CB and adult PBMC freshly isolated (A), or cultured for 1 wk (B) with IL-7 and pan $\gamma\delta$ TCR antibody: In each case, cells were prestimulated with PMA + ionomycin for 6 h. (C) pSTAT3 and pSTAT5 levels assessed by flow cytometry in gated $V\delta 2^+$ cells from fresh CB or adult PBMC (Left), or after 1 wk of culture with anti-CD3 + IL-2 (Right), in each case followed by 30-min IL-7 stimulation (open areas) or control (ctrl, shaded areas).

IFN- γ -competent cells (Fig. 6B and Fig. S7B). Comparing the main $\gamma\delta$ cell subsets: 1-wk culture with IL7 + TCR agonists sustained absolute numbers of $V\delta 1^+$ cells but IL-17 monoproducers expanded by ~ 50 -fold, compared with no significant increase in IFN- γ -competent cells, whereas $V\delta 2^+$ cell numbers increased ~ 10 -fold within which IL-17 monoproducers expanded by >20 -fold, compared with only a 10-fold increase in IFN- γ -competent cells. Hence, as in the mouse, the effects of IL-7 + TCR agonists are strongly biased toward IL-17 competence. Consistent with $\gamma\delta$ cell activation, $\sim 100\%$ lost the naive T-cell marker CD45RA, up-regulated ICOS, and expressed CD161, a marker of human IL-17-producing T cells (30) (Fig. S7B and C). When fresh or 1-wk cultures of CB or PBMC were freshly stimulated for 30 min with IL-7, all showed increased STAT5 phosphorylation, which did not therefore correlate with IL-17 competence. Conversely, STAT3 activation was measurable only in CB-derived $V\delta 2^+$ cells when cultured for 1 wk and then stimulated with IL-7 (Fig. 6C and Fig. S8A). Thus, as in mouse, IL-7-dependent STAT3 activation is highly selective.

CB $V\delta 2^+$ cells cultured for 1 wk with IL-7 + TCR agonist and stimulated for 2 h with PMA + ionomycin showed conspicuous reductions in RNA for T-bet, IL-2, and IFN- γ , with corresponding increases in IL-17A, IL-17F, and IL-22 RNAs (Fig. S8B). Indeed, a small number of IL-22-expressing cells was evoked, with the majority coproducing IL-17 (Fig. S8C). Again, these results were specifically due to IL-7, because IL-2 + TCR agonists skewed CB cells toward IFN- γ , with ~ 10 -fold fewer cells expressing IL-17 (Fig. S8D).

Discussion

This study identifies a pathway selectively activating the production of IL-17 by $\gamma\delta$ T cells. It operates in vivo and is conserved in mice and humans. It broadens our perspectives on the biology of IL-7 and has clinical relevance, given that IL-7 is used to promote lymphocyte expansion in cancer patients and in bone marrow transplantation (31) and given that protocols are being sought to maintain and expand $\gamma\delta$ cells for adoptive immunotherapy. Conversely, IL-7 blockade is being considered for inflammatory diseases.

Although a specific cytokine may not be essential for the development and survival of a particular lymphocyte subset, its capacity to regulate such cells is important. Such is the case for IL-7 and memory $CD8^+ \alpha\beta$ T cells, which are unaffected by IL-7 depletion but are nonetheless substantially expanded by IL-7, evoking an accumulation of $CD44^{hi}CD8^+ \alpha\beta$ T cells (32, 33). Likewise, IL-17-producing $\gamma\delta$ cells may not depend on STAT3 (15), but they are rapidly responsive to IL-23 that signals via STAT3 (10). In this vein, this study identifies a capacity of IL-7 to activate STAT3 preferentially in $\gamma\delta$ cells competent to produce IL-17, markedly expanding and activating such cells and promoting their functional responsiveness, for example, increased cytolytic potential. This activation is a selective role for IL-7 that for $\gamma\delta$ cells has hitherto been regarded as a generic regulator of development and homeostasis for all $\gamma\delta$ subsets (17, 34). This role of IL-7 offers parallels with its reported requirement to maintain $TCR\alpha\beta^+$ Th17 cells, although a key difference is that the effects of IL-7 in that case were mediated by STAT5 (35), which seems paradoxical given that STAT5 can antagonize Th17 differentiation. By contrast, the role of IL-7 described here is in large part mediated by STAT3, emphasizing the importance of a relatively poorly understood phenomenon—namely, how different cytokines use different signaling pathways to effect specific roles.

Like the effects of IL-7 on $\alpha\beta$ T cells (36, 37), IL-7-induced $\gamma\delta^{27-}$ expansion in vivo occurs in the periphery, but unlike for $\alpha\beta$ T cells, this expansion does not require prior lymphodepletion, emphasizing the capacity of IL-7 to act selectively on $\gamma\delta^{27-}$ cells in physiologic situations. Indeed, blocking IL-7R almost completely abrogated the expansion of LN IL-17-producing $\gamma\delta$ cells in response to IMQ, although it left the expansion of IFN- γ -producing cells largely untouched. Correspondingly blocking IL-7R inhibited the development of inflammatory lesions. Furthermore, increased IL-7 levels are detected in vivo after TLR activation (38) and in autoimmune diseases, such as rheumatoid arthritis (39), systemic juvenile rheumatoid arthritis (40), multiple sclerosis (41), and psoriasis (42), suggesting scenarios where potential dysregulation of IL-17-competent $\gamma\delta$ cells should be investigated. Indeed, IL-17-producing $\gamma\delta$ cells were recently described in psoriatic skin (11, 20, 43).

$\gamma\delta$ cells are not confined to T-cell zones and may access reticular stromal cells that express IL-7 (44), potentially in the context of tissue-draining antigens. Thus, the capacity of IL-7 to promote $\gamma\delta^{27-}$ cell activation in response to TCR agonists provides an important perspective on cells commonly assigned to innate immunity. Additionally, we have shown that IL-7 selectively expands $CD44^{hi} \gamma\delta^{27-}$ cells from the peritoneum, where $CD44^{hi} \gamma\delta$ T cells are strongly implicated in defense against bacterial infection (45).

Finally, IL-7 appears most abundant in neonatal mice, which is when lymphoid compartments are being filled according to homeostatic mechanisms and when murine IL-17-producing $\gamma\delta$ cells, largely derived from fetal progenitors, are most abundant. Indeed, IL-7 may throughout life mobilize IL-17-producing $\gamma\delta$ cells from a “self-renewing” pool set down in the fetus. It is also striking that the major evocation of human IL-17-producing $\gamma\delta$ cells is from CB. Interestingly, two studies using cytokines established to promote Th17 cells used CB to evoke small numbers of IL-17-producing $\gamma\delta$ cells (46, 47). $\gamma\delta$ cells are functionally precocious relative to $\alpha\beta$ T cells in mice and in humans, and one of their major biological contributions may be to protect neonates (29, 48, 49). Moreover, inflammatory immunopathologies may reflect inappropriate mobilization of cells laid down in the fetal/neonatal period. In pursuing this hypothesis, the major and selective potential of IL-7 needs now to be considered in immunoprotection and immunopathologies. This study also implies reciprocal selective roles of IL-2 and IL-15 in regulating IFN- γ -competent $\gamma\delta$ cells, which may be germane to the resurgent clinical use of these reagents.

Materials and Methods

Cell preparation, flow cytometry, PCR, and cytokine measurements were performed as described in *SI Materials and Methods*.

Murine and Human Samples. For methods related to animals and human samples, see *SI Materials and Methods*. In some experiments, mouse in vivo i.p. injections included PBS or recombinant mouse IL-7 [rml-IL-7 (R&D Systems), 5 µg per mouse every 2 d for 1 wk]. In other experiments, a daily dose of 50 mg of Imiquimod (5% IMQ cream; Meda AB) or control cream (Vaseline) was applied to shaved backs of mice for 3 d. Anti-IL-7R (clone A7R34) or rat IgG control treatment was performed by i.p. injection (1 mg per mouse) on days -1 and +2 relative to IMQ application. A7R34 was obtained from Biologend or, for some experiments, we made A7R34 from hybridoma (50).

Cell Culture. Cells were incubated for 1, 2, 3, or 4 d with IL-2 (100 U/mL; Immunotools), IL-7, IL-6, IL-15, and IL-21 (all 20 ng/mL; R&D Systems). Where indicated, anti-TCR $\gamma\delta$ (GL3: 1 or 10 µg/mL), IgG1 κ isotype control, and anti-CD107a/b antibodies (1D4B, M3/84; Biologend) were also added. After culture, dead cells were removed by Ficol-Hypaque centrifugation (GE Healthcare). In some experiments, cells were preincubated with STAT3 inhibitor VII (Calbiochem) for 1 h before addition of IL-7. For human studies, cells were cultured for 1 wk with IL-7 (20 ng/mL; R&D Systems) or IL-2 (100 U/mL;

Immunotools) in wells coated with pan anti- $\gamma\delta$ TCR (1 µg/mL, IMMU510; Beckman).

ImageStream Acquisition and Analysis. Samples (4×10^7 cells per mL in 60 µL of wash buffer with 1 µg/mL PI) were acquired on a 5-laser 6-Channel ISx Imaging Flow Cytometer with 40 \times magnification controlled by INSPIRE software and fully ASSIST calibrated (Amnis).

ACKNOWLEDGMENTS. We thank B. Silva-Santos and J. Ribot (Lisbon), G. Turchinovich and M. Wencker [London Research Institute (LRI) and Cancer Research UK (CRUK)], and Susan John (King's College London; KCL) for advice, reagents, and assistance; Warren Leonard (National Institutes of Health) for access to data prepublication; D. Bonnet and colleagues (LRI, CRUK) for cord blood; and the Flow Cytometry Laboratories of CRUK, KCL, and the Comprehensive Biomedical Research Centre (cBRC), especially S. Purewal (CRUK), for work with Image Stream. We acknowledge grants from the Wellcome Trust (to A.C.H. and to D.J.P.); the Medical Research Council (MRC) for Programme and MRC Transplantation Centre grants to A.C.H. (co-principal investigator) and for core support (to A.J.P.); CRUK; and the Marie Curie Programme for support of M.-L.M.

- Harrington LE, et al. (2005) Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol* 6(11):1123–1132.
- Park H, et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat Immunol* 6(11):1133–1141.
- Stockinger B, Veldhoen M (2007) Differentiation and function of Th17 T cells. *Curr Opin Immunol* 19(3):281–286.
- Hayday AC (2009) Gammadelta T cells and the lymphoid stress-surveillance response. *Immunity* 31(2):184–196.
- Lockhart E, Green AM, Flynn JL (2006) IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. *J Immunol* 177(7):4662–4669.
- Umemura M, et al. (2007) IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. *J Immunol* 178(6):3786–3796.
- Hamada S, et al. (2008) IL-17A produced by gammadelta T cells plays a critical role in innate immunity against listeria monocytogenes infection in the liver. *J Immunol* 181(5):3456–3463.
- Ribot JC, et al. (2009) CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. *Nat Immunol* 10(4):427–436.
- Ribot JC, et al. (2010) Cutting edge: Adaptive versus innate receptor signals selectively control the pool sizes of murine IFN- γ - or IL-17-producing $\gamma\delta$ T cells upon infection. *J Immunol* 185(11):6421–6425.
- Sutton CE, et al. (2010) Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. *Immunity* 31(2):331–341.
- Cai Y, et al. (2011) Pivotal role of dermal IL-17-producing $\gamma\delta$ T cells in skin inflammation. *Immunity* 35(4):596–610.
- Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. *Annu Rev Immunol* 27:485–517.
- Puel A, et al. (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. *Science* 332(6025):65–68.
- Jensen KD, et al. (2008) Thymic selection determines gammadelta T cell effector fate: Antigen-naïve cells make interleukin-17 and antigen-experienced cells make interferon gamma. *Immunity* 29(1):90–100.
- Shibata K, et al. (2011) Notch-Hes1 pathway is required for the development of IL-17-producing $\gamma\delta$ T cells. *Blood* 118(3):586–593.
- Caccamo N, et al. (2011) Differentiation, phenotype, and function of interleukin-17-producing human V γ 9V δ 2 T cells. *Blood* 118(1):129–138.
- Baccala R, et al. (2005) Gamma delta T cell homeostasis is controlled by IL-7 and IL-15 together with subset-specific factors. *J Immunol* 174(8):4606–4612.
- Shibata K, et al. (2008) Identification of CD25⁺ gamma delta T cells as fetal thymus-derived naturally occurring IL-17 producers. *J Immunol* 181(9):5940–5947.
- Duan J, Chung H, Troy E, Kasper DL (2010) Microbial colonization drives expansion of IL-1 receptor 1-expressing and IL-17-producing gamma/delta T cells. *Cell Host Microbe* 7(2):140–150.
- Pantelyushin S, et al. (2012) Ror γ ⁺ innate lymphocytes and $\gamma\delta$ T cells initiate psoriasis-forming plaque formation in mice. *J Clin Invest* 122(6):2252–2256.
- Barata JT, Cardoso AA, Nadler LM, Boussiotis VA (2001) Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). *Blood* 98(5):1524–1531.
- Lin JX, et al. (1995) The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. *Immunity* 2(4):331–339.
- Pallard C, et al. (1999) Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors. *Immunity* 10(5):525–535.
- Barata JT, et al. (2004) Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. *J Exp Med* 200(5):659–669.
- Yang XP, et al. (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. *Nat Immunol* 12(3):247–254.
- Hirota K, et al. (2011) Fate mapping of IL-17-producing T cells in inflammatory responses. *Nat Immunol* 12(3):255–263.
- Betts MR, et al. (2003) Sensitive and viable identification of antigen-specific CD8⁺ T cells by a flow cytometric assay for degranulation. *J Immunol Methods* 281(1-2): 65–78.
- DeBarros A, Chaves-Ferreira M, d'Orey F, Ribot JC, Silva-Santos B (2011) CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human $\gamma\delta$ peripheral blood lymphocytes. *Eur J Immunol* 41(1): 195–201.
- Gibbons DL, et al. (2009) Neonates harbour highly active gammadelta T cells with selective impairments in preterm infants. *Eur J Immunol* 39(7):1794–1806.
- Maggi L, et al. (2010) CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. *Eur J Immunol* 40(8):2174–2181.
- Capitini CM, Chisti AA, Mackall CL (2009) Modulating T-cell homeostasis with IL-7: Preclinical and clinical studies. *J Intern Med* 266(2):141–153.
- Kieper WC, et al. (2002) Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8⁺ T cells. *J Exp Med* 195(12):1533–1539.
- Tan JT, et al. (2002) Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8⁺ cells but are not required for memory phenotype CD4⁺ cells. *J Exp Med* 195(12):1523–1532.
- French JD, Roark CL, Born WK, O'Brien RL (2005) Gammadelta T cell homeostasis is established in competition with alphabeta T cells and NK cells. *Proc Natl Acad Sci USA* 102(41):14741–14746.
- Liu X, et al. (2010) Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. *Nat Med* 16(2):191–197.
- Komschlies KL, et al. (1994) Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. *J Immunol* 152(12):5776–5784.
- Geiselhart LA, et al. (2001) IL-7 administration alters the CD4:CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation. *J Immunol* 166(5):3019–3027.
- Sawa Y, et al. (2009) Hepatic interleukin-7 expression regulates T cell responses. *Immunity* 30(3):447–457.
- van Roon JA, et al. (2005) Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4⁺ T cells and macrophages. *Arthritis Rheum* 52(6):1700–1710.
- De Benedetti F, et al. (1995) Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. *J Rheumatol* 22(8):1581–1585.
- Haas J, Korporal M, Schwarz A, Balint B, Wildemann B (2011) The interleukin-7 receptor α chain contributes to altered homeostasis of regulatory T cells in multiple sclerosis. *Eur J Immunol* 41(3):845–853.
- Bonifati C, et al. (1997) Increased interleukin-7 concentrations in lesional skin and in the sera of patients with plaque-type psoriasis. *Clin Immunol Immunopathol* 83(1):41–44.
- Laggner U, et al. (2011) Identification of a novel proinflammatory human skin-homing V γ 9V δ 2 T cell subset with a potential role in psoriasis. *J Immunol* 187(5):2783–2793.
- Link A, et al. (2007) Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. *Nat Immunol* 8(11):1255–1265.
- Bonneville M, O'Brien RL, Born WK (2010) Gammadelta T cell effector functions: A blend of innate programming and acquired plasticity. *Nat Rev Immunol* 10(7):467–478.
- Moens E, et al. (2011) IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17. *J Leukoc Biol* 89(5):743–752.
- Ness-Schwickerath KJ, Morita CT (2011) Regulation and function of IL-17A- and IL-22-producing $\gamma\delta$ T cells. *Cell Mol Life Sci* 68(14):2371–2390.
- Hayday AC (2000) [gamma][delta] cells: A right time and a right place for a conserved third way of protection. *Annu Rev Immunol* 18:975–1026.
- Ramsburg E, Tigelaar R, Craft J, Hayday A (2003) Age-dependent requirement for gammadelta T cells in the primary but not secondary protective immune response against an intestinal parasite. *J Exp Med* 198(9):1403–1414.
- Sudo T, et al. (1993) Expression and function of the interleukin 7 receptor in murine lymphocytes. *Proc Natl Acad Sci USA* 90(19):9125–9129.